CLINDAMYCIN PHOSPHATE

Post-LOE

clindamycin phosphate

ANDATOPICALGEL
Approved
Aug 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

CLINICAL PHARMACOLOGY Pharmacokinetics: In an open-label, parallel group study of 24 patients with acne vulgaris, once-daily topical administration of approximately 3 to 12 grams/day of clindamycin phosphate for 5 days resulted in peak plasma clindamycin concentrations that were less than 5.5…

Clinical Trials (4)

NCT07205107N/ARecruiting

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Started Oct 2025
NCT03122457Phase 2Completed

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

Started Jan 2017
NCT01915732Phase 3Completed

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

Started Apr 2013
1,018 enrolled
Acne Vulgaris
NCT01915758Phase 1Completed

W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers

Started Nov 2008
64 enrolled
Acne Vulgaris